HRH1 and inflammatory bowel disease: Although a reduction in abdominal pain and symptoms has been reported in IBS patients upon treatment with the histamine receptor H1 antagonist ebastine, histamine antagonists turned out to have limited effect in IBD patients, possibly because MC mediators other than histamine play a major role.